Log in
NASDAQ:PPD

PPD Stock Forecast, Price & News

$32.88
-0.27 (-0.81 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$32.12
Now: $32.88
$33.34
50-Day Range
$32.25
MA: $35.09
$36.99
52-Week Range
$10.61
Now: $32.88
$37.51
Volume1.68 million shs
Average Volume1.40 million shs
Market Capitalization$11.46 billion
P/E Ratio33.55
Dividend YieldN/A
BetaN/A
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The Laboratory Services segment offers bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. The company operates in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PPD
CUSIPN/A
CIKN/A
Phone910-251-0081
Employees23,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.03 billion

Profitability

Miscellaneous

Market Cap$11.46 billion
Next Earnings Date3/3/2021 (Estimated)
OptionableNot Optionable
$32.88
-0.27 (-0.81 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PPD News and Ratings via Email

Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PPD (NASDAQ:PPD) Frequently Asked Questions

How has PPD's stock price been impacted by COVID-19?

PPD's stock was trading at $25.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PPD stock has increased by 27.6% and is now trading at $32.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PPD?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PPD in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PPD
.

When is PPD's next earnings date?

PPD is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for PPD
.

How were PPD's earnings last quarter?

PPD (NASDAQ:PPD) announced its quarterly earnings results on Tuesday, October, 27th. The company reported $0.30 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.15 by $0.15. The firm had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.17 billion.
View PPD's earnings history
.

What guidance has PPD issued on next quarter's earnings?

PPD updated its fourth quarter 2020 After-Hours earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.256-1.298 billion, compared to the consensus revenue estimate of $1.15 billion.

What price target have analysts set for PPD?

16 equities research analysts have issued 1-year price objectives for PPD's stock. Their forecasts range from $20.00 to $42.00. On average, they expect PPD's stock price to reach $34.80 in the next year. This suggests a possible upside of 5.8% from the stock's current price.
View analysts' price targets for PPD
.

Who are some of PPD's key competitors?

What other stocks do shareholders of PPD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PPD investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), salesforce.com (CRM), Pfizer (PFE), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), Raytheon Technologies (RTX) and Verizon Communications (VZ).

Who are PPD's key executives?

PPD's management team includes the following people:
  • Mr. David S. Simmons, Chairman & CEO (Age 55)
  • Mr. Christopher G. Scully, Exec. VP, CFO, Treasurer & Assistant Sec. (Age 49)
  • Mr. William J. Sharbaugh, Chief Operating Officer (Age 57)
  • Mr. Glen Donovan, Chief Accounting Officer (Age 46)
  • Mr. B. Judd Hartman, Exec. VP, Gen. Counsel & Chief Admin. Officer (Age 56)

When did PPD IPO?

(PPD) raised $1.5 billion in an IPO on Thursday, February 6th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair served as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers.

What is PPD's stock symbol?

PPD trades on the NASDAQ under the ticker symbol "PPD."

Who are PPD's major shareholders?

PPD's stock is owned by many different institutional and retail investors. Top institutional shareholders include LGT Capital Partners LTD. (0.06%), Syquant Capital Sas (0.02%), Amalgamated Bank (0.01%), Convergence Investment Partners LLC (0.00%), Dupont Capital Management Corp (0.00%) and Xponance Inc. (0.00%). Company insiders that own PPD stock include Carlyle Group Management LLC, Christopher Fikry, Colin Hill, David Michael Johnston, David S Simmons, Glen Donovan, Jill Pellegrino, Karen Kaucic, Ronald E Garrow and William J Sharbaugh.
View institutional ownership trends for PPD
.

Which institutional investors are selling PPD stock?

PPD stock was sold by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD.. Company insiders that have sold PPD company stock in the last year include Carlyle Group Management LLC, Colin Hill, David Michael Johnston, Glen Donovan, Jill Pellegrino, Karen Kaucic, and Ronald E Garrow.
View insider buying and selling activity for PPD
.

Which institutional investors are buying PPD stock?

PPD stock was purchased by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Amalgamated Bank, Convergence Investment Partners LLC, Dupont Capital Management Corp, Xponance Inc., Nisa Investment Advisors LLC, and NEXT Financial Group Inc. Company insiders that have bought PPD stock in the last two years include Christopher Fikry, David S Simmons, and William J Sharbaugh.
View insider buying and selling activity for PPD
.

How do I buy shares of PPD?

Shares of PPD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PPD's stock price today?

One share of PPD stock can currently be purchased for approximately $32.88.

How big of a company is PPD?

PPD has a market capitalization of $11.46 billion and generates $4.03 billion in revenue each year. The company earns $47.82 million in net income (profit) each year or $0.98 on an earnings per share basis. PPD employs 23,000 workers across the globe.

What is PPD's official website?

The official website for PPD is www.ppdi.com.

How can I contact PPD?

PPD's mailing address is 929 NORTH FRONT STREET, WILMINGTON NC, 28401. The company can be reached via phone at 910-251-0081 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.